Issue: February 2011
February 01, 2011
1 min read
Save

Rotavirus vaccines helped reduce hospitalization-related illness

Anderson EJ. Pediatrics. 2011;127:e264-e270.

Issue: February 2011
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Hospital-associated rotavirus declined more than 60% after rotavirus vaccination became routine practice compared with prior seasons, mirroring an even greater reduction in community-acquired cases of about 82%, according to researchers at Children’s Memorial Hospital in Chicago.

Evan J. Anderson, MD, and colleagues assessed community- and hospital-acquired rotavirus, influenza and respiratory syncytial virus (RSV) through antigen testing between 2003 and 2008.

They found that hospitalizations for community-acquired rotavirus declined from a median of 1.62 per 100 admissions in the 2003 to 2006 seasons to 0.28 per 100 in the 2007-2008 season.

The researchers said improvements in infection control measures, such as hand-hygiene compliance, did not seem to correlate with the reduction in rotavirus because the influenza and RSV rates remained stable.

“Although we noted continued improvement in our independently observed hand-hygiene compliance, a corresponding decrease in the [hospital-acquired] and [community-acquired] rotavirus transmission rate did not occur. A potential explanation is that the 10% absolute increase in hand-hygiene compliance at [Children’s Memorial Hospital] was insufficient to substantially impact [hospital-acquired] rates,” the researchers wrote. “Our data confirm the hypothesis that vaccination, by impacting [community-acquired] rotavirus hospital admissions, might decrease [hospital-acquired] rotavirus rates.”

Disclosure: Dr. Anderson reports serving on the speaker’s bureau for Merck, consulting for Merck and GlaxoSmithKline, and receiving research support from Merck, Meridian Bioscience Inc. and Clearview, and financial compensation for writing a review article for Medscape CME.

Twitter Follow InfectiousDiseaseNews.com on Twitter.